daptomycin + daptomycin
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
End-stage Renal Disease
Conditions
End-stage Renal Disease, Renal Failure Chronic Requiring Hemodialysis
Trial Timeline
Apr 29, 2009 → Jul 17, 2009
NCT ID
NCT00882557About daptomycin + daptomycin
daptomycin + daptomycin is a phase 1 stage product being developed by Merck for End-stage Renal Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00882557. Target conditions include End-stage Renal Disease, Renal Failure Chronic Requiring Hemodialysis.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01216241 | Phase 3 | Terminated |
| NCT00882557 | Phase 1 | Completed |
Competing Products
20 competing products in End-stage Renal Disease